One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Human Papillomavirus and Incidence and Survival of Oropharyngeal Cancers.
Gillison, Maura L. MD, PhD 1,2,,
doi : 10.1200/JCO.23.00224
Volume 41(17) pgs. 3079-3274 June 10, 2023
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States.
Chaturvedi, Anil K.; Engels, Eric A.; Pfeiffer, Ruth M.; Hernandez, Brenda Y.; Xiao, Weihong; Kim, Esther; Jiang, Bo; Goodman, Marc T.; Sibug-Saber, Maria; Cozen, Wendy; Liu, Lihua; Lynch, Charles F.; Wentzensen, Nicolas; Jordan, Richard C.; Altekruse, Sean; Anderson, William F.; Rosenberg, Philip S.; Gillison, Maura L.
doi : 10.1200/JCO.22.02625
Recent increases in incidence and survival of oropharyngeal cancers in the United States have been attributed to human papillomavirus (HPV) infection, but empirical evidence is lacking.
Antibiotic Therapy: The Cornerstone of Iatrogenic Resistance to Immune Checkpoint Inhibitors.
Pinato, David J. MD, MRes, MRCP, PhD 1,2,,; Cortellini, Alessio MD, PhD 1,3,
doi : 10.1200/JCO.23.00049
Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer.
Laws, Alison MD, MPH 1,; Punglia, Rinaa S. MD, MPH 2
doi : 10.1200/JCO.23.00455
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis.
Subbiah, Vivek MD 1,2,,; Kurzrock, Razelle MD 3,4,
doi : 10.1200/JCO.22.02833
Impact of Heatwaves on Cancer Care Delivery: Potential Mechanisms, Health Equity Concerns, and Adaptation Strategies.
Hassan, Abbas M. MD 1; Nogueira, Leticia MPH, PhD 2; Lin, Yu-Li MS 3,; Rogers, Jane E. PharmD, BCOP 4; Nori-Sarma, Amruta PhD 5; Offodile, Anaeze Chidiebele II MD, MPH 1,3,6,,
doi : 10.1200/JCO.22.01951
Accelerating the Evolution of Immune-Related Enterocolitis Management.
Faleck, David M. MD 1,2,,; Dougan, Michael MD, PhD 3,; Tello, Monique MD 4,; Grossman, Joseph E. MD 4,; Moss, Alan C. MD 5,; Postow, Michael A. MD 2,6,
doi : 10.1200/JCO.22.02914
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
Lazzeroni, Matteo MD 1; Puntoni, Matteo PhD 2,; Guerrieri-Gonzaga, Aliana MSc 1; Serrano, Davide MD 1; Boni, Luca MD 3,; Buttiron Webber, Tania RN 4; Fava, Marianna PhD 4; Briata, Irene M. MSc 4; Giordano, Livia MD 5; Digennaro, Maria MD 6; Cortesi, Laura MD 7,; Falcini, Fabio MD 8,9; Serra, Patrizia PhD 9; Avino, Franca MD 10; Millo, Francesco MD 11; Cagossi, Katia MD 12; Gallerani, Elisa MD 13,; De Simone, Alessia MD 14; Cariello, Anna MD 15; Aprile, Giuseppe MD 16,; Renne, Maria MD 17; Bonanni, Bernardo MD 1,; DeCensi, Andrea MD 1,4,18,
doi : 10.1200/JCO.22.02900
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study.
Eng, Lawson MD, SM 1,2,; Sutradhar, Rinku PhD 3,4; Niu, Yue MSc 3; Liu, Ning PhD 3; Liu, Ying MSc 3; Kaliwal, Yosuf MSc 3; Powis, Melanie L. MSc 1; Liu, Geoffrey MD, MSc 1,2,; Peppercorn, Jeffrey M. MD, MPH 5,; Bedard, Philippe L. MD 1,2,; Krzyzanowska, Monika K. MD, MPH 1,2,3,
doi : 10.1200/JCO.22.00074
Antibiotic exposure before immune checkpoint inhibitor (ICI) treatment can negatively affect outcomes through alteration in the gut microbiome, but large-scale evaluations are lacking. We performed a population-level retrospective cohort study to evaluate the impact of antibiotic exposure before starting ICI on overall survival (OS).
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
Flaadt, Tim MD 1,; Ladenstein, Ruth L. MD, PhD 2,3,; Ebinger, Martin MD 1,; Lode, Holger N. MD 4; Arnardottir, Helga Bjork MSc 5; Poetschger, Ulrike PhD 5; Schwinger, Wolfgang MD 6; Meisel, Roland MD 7,; Schuster, Friedhelm R. MD 7; Doring, Michaela MD 1; Ambros, Peter F. PhD 8; Queudeville, Manon MD 1,; Fuchs, Jorg MD 9; Warmann, Steven W. MD 9; Schafer, Jurgen MD 10; Seitz, Christian MD 1,11,; Schlegel, Patrick MD 12,; Brecht, Ines B. MD 1,; Holzer, Ursula MD 1,; Feuchtinger, Tobias MD 13; Simon, Thorsten MD 14,; Schulte, Johannes H. MD 15; Eggert, Angelika MD 15,; Teltschik, Heiko-Manuel MD 16; Illhardt, Toni MD 1; Handgretinger, Rupert MD 1; Lang, Peter MD 1,11,
doi : 10.1200/JCO.22.01630
Patients with relapsed high-risk neuroblastoma (rHR-NB) have a poor prognosis. We hypothesized that graft-versus-neuroblastoma effects could be elicited by transplantation of haploidentical stem cells (haplo-SCT) exploiting cytotoxic functions of natural killer cells and their activation by the anti-GD2 antibody dinutuximab beta (DB).
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification.
Bender, Hannah G. BA 1; Irwin, Meredith S. MD 2; Hogarty, Michael D. MD 3,; Castleberry, Robert MD 4; Maris, John M. MD 3,; Kao, Pei-Chi MPH 1; Zhang, Fan F. MS 5; Naranjo, Arlene PhD 5,; Cohn, Susan L. MD 6,; London, Wendy B. PhD 1,
doi : 10.1200/JCO.22.01946
In 2006, Children's Oncology Group (COG) reclassified subgroups of toddlers diagnosed with neuroblastoma from high-risk to intermediate-risk, when the age cutoff for high-risk assignment was raised from 365 days (12 months) to 547 days (18 months).
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
Youssef, Gilbert MD 1; Rahman, Rifaquat MD 2,; Bay, Camden PhD 3,; Wang, Wei PhD 4,5,6; Lim-Fat, Mary Jane MD, MSc, FRCPC 7; Arnaout, Omar MD 8; Bi, Wenya Linda MD, PhD 8,; Cagney, Daniel N. MD 9; Chang, Yuh-Shin MDCM, PhD 10,11,; Cloughesy, Timothy F. MD 12,13,; DeSalvo, Matthew MD 3,; Ellingson, Benjamin M. PhD 14,15,16,17,; Flood, Thomas F. MD, PhD 3; Gerstner, Elizabeth R. MD 18,; Gonzalez Castro, L. Nicolas MD, PhD 1,4,; Guenette, Jeffrey P. MD 3; Kim, Albert E. MD 18; Lee, Eudocia Q. MD, MPH 1,; McFaline-Figueroa, Jose R. MD, PhD 1; Potter, Christopher A. MD 3; Reardon, David A. MD 1,; Huang, Raymond Y. MD, PhD 3,; Wen, Patrick Y. MD 1,
doi : 10.1200/JCO.22.01579
The Response Assessment in Neuro-Oncology (RANO) criteria are widely used in high-grade glioma clinical trials. We compared the RANO criteria with updated modifications (modified RANO [mRANO] and immunotherapy RANO [iRANO] criteria) in patients with newly diagnosed glioblastoma (nGBM) and recurrent GBM (rGBM) to evaluate the performance of each set of criteria and inform the development of the planned RANO 2.0 update.
Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer.
Vachon, Celine M. PhD 1,,; Scott, Christopher G. MS 2; Norman, Aaron D. MPH 1; Khanani, Sadia A. MD 3,; Jensen, Matthew R. BS 2; Hruska, Carrie B. PhD 3,; Brandt, Kathleen R. MD 3; Winham, Stacey J. PhD 4; Kerlikowske, Karla MD 5
doi : 10.1200/JCO.22.01153
Artificial intelligence (AI) algorithms improve breast cancer detection on mammography, but their contribution to long-term risk prediction for advanced and interval cancers is unknown.
Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance).
Boughey, Judy C. MD 1,,; Rosenkranz, Kari M. MD 2; Ballman, Karla V. PhD 3,; McCall, Linda MS 4; Haffty, Bruce G. MD 5,; Cuttino, Laurie W. MD 6,; Kubicky, Charlotte D. MD 7; Le-Petross, Huong T. MD 8; Giuliano, Armando E. MD 9,; Van Zee, Kimberly J. MS, MD 10; Hunt, Kelly K. MD 8,; Hahn, Olwen M. MD 11,; Carey, Lisa A. MD 12,; Partridge, Ann H. MD, MPH 13,
doi : 10.1200/JCO.22.02553
Breast-conserving therapy (BCT) is the preferred treatment for unifocal breast cancer (BC). The oncologic safety of BCT for multiple ipsilateral breast cancer (MIBC) has not been demonstrated in a prospective study.
Impact of the COVID-19 Pandemic on Cancer Screening Delays.
Zhang, Xiaochen MPH, PhD 1; Elsaid, Mohamed I. PhD 2,3; DeGraffinreid, Cecilia MHS 1; Champion, Victoria L. PhD 4; Paskett, Electra D. PhD 1,; for the Impact of COVID-19 on Behaviors across the Cancer Control Continuum in Ohio group; Brock, Guy; Washington, Chasity; Ferketich, Amy K.; Hampel, Heather; Aker, Heather
doi : 10.1200/JCO.22.01704
To examine delays in cancer screenings during the COVID-19 pandemic. METHODS: Participants from previous studies (N = 32,989) with permissions to be recontacted were invited to complete a survey between June and November 2020.
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.
Krauss, Daniel J. MD 1,; Karrison, Theodore PhD 2; Martinez, Alvaro A. MD 3; Morton, Gerard MD 4,; Yan, Di PhD 1; Bruner, Deborah Watkins PhD, RN 5,; Movsas, Benjamin MD 6,; Elshaikh, Mohamed MD 6; Citrin, Deborah MD 7,; Hershatter, Bruce MD 5; Michalski, Jeff M. MD, MBA 8,; Efstathiou, Jason Alexander MD, PhD 9,; Currey, Adam MD 10; Kavadi, Vivek S. MD 11,; Cury, Fabio L. MD 12,; Lock, Michael MD 13,; Raben, Adam MD 14,15,; Seaward, Samantha Andrews MD 16; El-Gayed, Ali MD 17; Rodgers, Joseph P. 18; Sandler, Howard M. MD 19,
doi : 10.1200/JCO.22.02390
It remains unknown whether or not short-term androgen deprivation (STAD) improves survival among men with intermediate-risk prostate cancer (IRPC) treated with dose-escalated radiotherapy (RT).
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.
Movsas, Benjamin MD 1,,; Rodgers, Joseph P. MS 2; Elshaikh, Mohamed A. MD 1; Martinez, Alvaro A. MD 3; Morton, Gerard C. MD 4,; Krauss, Daniel J. MD 5; Yan, Di PhD 5; Citrin, Deborah E. MD 6; Hershatter, Bruce W. MD 7; Michalski, Jeff M. MD 8,; Ellis, Rodney J. MD 9,10; Kavadi, Vivek S. MD 11,; Gore, Elizabeth M. MD 12; Gustafson, Gary S. MD 13; Schulz, Craig A. MD 14; Velker, Vikram M. MD 15; Olson, Adam C. MD 16,; Cury, Fabio L. MD 17,; Papagikos, Michael A. MD 18; Karrison, Theodore G. PhD 19; Sandler, Howard M. MD 20,; Bruner, Deborah W. PhD, RN 7,
doi : 10.1200/JCO.22.02389
To report patient-reported outcomes (PROs) of a phase III trial evaluating total androgen suppression (TAS) combined with dose-escalated radiation therapy (RT) for patients with intermediate-risk prostate cancer.
Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
Sarfaty, Michal MD 1,2,3,; Golkaram, Mahdi PhD 4,; Funt, Samuel A. MD 1,; Al-Ahmadie, Hikmat MD 5,; Kaplan, Shannon MSc 4,; Song, Fan MSc 4,; Regazzi, Ashley BS 1; Makarov, Vladimir MSc 6; Kuo, Fengshen PhD 7,; Ostrovnaya, Irina PhD 8,; Seshan, Venkatraman PhD 8; Zhao, Chen MSc 4,; Greenbaum, Benjamin PhD 8,; Liu, Li MSc 4,; Rosenberg, Jonathan E. MD 1,,; Chan, Timothy A. MD 6,9,
doi : 10.1200/JCO.22.02144
Immune checkpoint blockade (ICB) therapy has significantly improved clinical outcomes in bladder cancer. Identification of correlates of benefit is critical to select appropriate therapy for individual patients.
Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
Long, Georgina V. MD, PhD, FRACP 1,2,3,4,5,,; Menzies, Alexander M. MD, PhD, FRACP 1,2,3,4,; Scolyer, Richard A. MD, FRCPA, FRCPath 1,2,5,6,7,
doi : 10.1200/JCO.22.02575
AB The role of neoadjuvant therapy is undergoing an historic shift in oncology. The emergence of potent immunostimulatory anticancer agents has transformed neoadjuvant therapy from a useful tool in minimizing surgical morbidity to a life-saving treatment with curative promise, led by research in the field of melanoma.
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer.
Akinboro, Oladimeji MD, MPH 1,,; Drezner, Nicole MD 1; Amatya, Anup PhD 1,; Runyan, Jin PhD 1; Fourie-Zirkelbach, Jeanne PhD 1; Zhao, Miao MD 1,; Bi, Youwei PhD 1; Korsah, Kwadwo PharmD 1; Mixter, Bronwyn BA 2; Tang, Shenghui PhD 1; Larkins, Erin MD 1; Pazdur, Richard MD 1,2; Beaver, Julia A. MD 1,2; Singh, Harpreet MD 1,2
doi : 10.1200/JCO.22.02509
On March 4, 2022, the US Food and Drug Administration (FDA) approved nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non-small-cell lung cancer (NSCLC).
Cost of Cancer in Adolescents and Young Adults in the United States: Results of the 2021 Report by Deloitte Access Economics, Commissioned by Teen Cancer America.
Parsons, Susan K. MD, MRP 1,2,,; Keegan, Theresa H.M. PhD, MS 3,; Kirchhoff, Anne C. PhD, MPH 4,; Parsons, Helen M. PhD, MPH 5; Yabroff, K. Robin PhD, MBA 6,; Davies, Simon J. DEd (hon) 7
doi : 10.1200/JCO.22.01985
The purpose of this report, commissioned by Teen Cancer America and performed by Deloitte Access Economics in 2021, was to estimate the total costs incurred by adolescent and young adults (AYAs) after cancer diagnosis in the United States (US) over their life course.
Secondary Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease Inform Gene Therapy Approaches.
Meisel, Roland MD
doi : 10.1200/JCO.23.00403
